Share chart Acrivon Therapeutics, Inc.
Extended chart
Simple chart
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. more details| IPO date | 2022-11-15 |
|---|---|
| ISIN | US0048901096 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.acrivon.com |
| Цена ао | 5.07 |
| Change price per day: | +7.3% (5.07) |
|---|---|
| Change price per week: | -1.81% (5.54) |
| Change price per month: | +5.43% (5.16) |
| Change price per 3 month: | -22.95% (7.06) |
| Change price per half year: | -33.9% (8.23) |
| Change price per year: | +7.3% (5.07) |
| Change price per 3 year: | -0% (5.44) |
| Change price per 5 year: | -0% (5.44) |
| Change price per 10 year: | -0% (5.44) |
| Change price per year to date: | -12.68% (6.23) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| RA Capital Management, L.P. | 4810508 | 21.25 |
| Perceptive Advisors LLC | 3007858 | 13.29 |
| Sands Capital Ventures, LLC | 1652605 | 7.3 |
| Citadel Advisors Llc | 1649659 | 7.29 |
| Wellington Management Group, LLP | 888130 | 3.92 |
| Marshall Wace LLP | 597469 | 2.64 |
| Blackrock Inc. | 565832 | 2.5 |
| Vanguard Group Inc | 475977 | 2.1 |
| NEA Management Company, LLC | 430252 | 1.9 |
| Federated Hermes, Inc. | 226375 | 1 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Range Cancer Therapeutics ETF | 2.03779 | 47.24 | 0.11955 |
| iShares Micro-Cap ETF | 0.02284 | 17.09 | 1.54048 |
| Avantis U.S Small Cap Equity ETF | 0.00853 | 27.77 | 1.68271 |
Schwab U.S. Small-Cap ETF
|
0.00415 | 17.47 | 1.51433 |
ProShares UltraPro Russell2000
|
0.0019 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.00053 | 5.92 | 1.47892 |
Schwab U.S. Broad Market ETF
|
0.00053 | 24.86 | 1.43354 |
| Vanguard Russell 2000 ETF | 0 | 17.16 | 1.48801 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Peter Blume-Jensen M.D., Ph.D. | Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer | 977.7k | 1963 (62 years) |
| Ms. Kristina Masson M.B.A., Ph.D. | Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director | 739.78k | 1981 (44 years) |
| Mr. Rasmus Holm-Jorgensen | Chief Financial Officer | 1M | 1972 (53 years) |
| Dr. Eric J. Devroe Ph.D. | Chief Operating Officer | 614.78k | 1979 (46 years) |
| Ms. Katharine Peterson CPA | Vice President of Finance & Accounting | N/A | |
| Dr. Adam D. Levy M.B.A., Ph.D. | Senior VP and Head of Investor Relations & Corporate Affairs | N/A | |
| Mr. Bruce Close | Vice President of Quality & Compliance | N/A | |
| Ms. Mary-Alice Miller J.D. | Chief Legal Officer | 587.11k | 1974 (51 year) |
| Ms. Parvin Miah | VP & Head of Human Resources | N/A | |
| Dr. Erick Gamelin M.D., Ph.D. | Chief Development Officer | 480.72k | 1958 (67 years) |
Address: United States, Watertown. MA, 480 Arsenal Way - open in Google maps, open in Yandex maps
Website: https://www.acrivon.com
Website: https://www.acrivon.com
